Stockreport

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Compass Therapeutics, Inc.  (CMPX) 
PDF Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advance [Read more]